| Identification | Back Directory | [Name]
GSK840 | [CAS]
2361146-30-5 | [Synonyms]
GSK840
tert-butyl 2-(4-(5-(methylcarbamoyl)-1H-benzo[d]imidazol-1-yl)phenyl)acetate | [Molecular Formula]
C21H23N3O3 | [MOL File]
2361146-30-5.mol | [Molecular Weight]
365.43 |
| Chemical Properties | Back Directory | [density ]
1.18±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
110 mg/mL in DMSO | [form ]
Solid | [pka]
14.16±0.46(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Biological Activity]
GSK840 is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, binds with high affinity to the RIP3 kinase domain with an IC50 of 0.9 nM, and inhibits kinase activity with an IC50 of 0.3 nM. | [in vitro]
GSK840 (GSK'840) (0.01-3 μM; 24 hours) blocks TNF-induced necroptosis in a concentration-dependent manner.
GSK840 binds the kinase domain and inhibits kinase activity with high specificity, targeting a broader range of pro-necrotic stimuli than can be achieved with RIP1 kinase inhibitors. Cell Viability Assay | Cell Line: | Human HT-29 cells (TNF 10 ng/ml + zVAD-fmk 20 μM + SMAC007 100 nM) | | Concentration: | 0.01-3 μM | | Incubation Time: | 24 hours | | Result: | Blocked TNF-induced necroptosis in a concentration-dependent manner. | | [target]
|
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|